Mr Prabhakar Rajan

Mr Rajan PrabhakarTel: 02034479194
Fax: 02034479303

University College Hospital at Westmoreland Street

Urological Cancers, Prostate Cancer

Professional background

Prabhakar Rajan is a member of the robotic surgery team, and has a specialist interest in the treatment of prostate cancer by robot-assisted radical prostatectomy. Mr. Rajan studied physiology and medicine at Cambridge University, and completed junior surgical and senior urological residencies in Edinburgh and Glasgow, respectively. After Fellowship training in robotic surgery at the Karolinska University Hospital, Stockholm, Sweden, he was appointed as a Consultant in Urology with an interest in general urology and laparoscopy within NHS Greater Glasgow and Clyde, and moved to UCLH and Barts Health NHS Trusts in October 2015.

Research interests

Mr. Rajan is one of only a handful of academic surgeons in the UK to be awarded a RCSEng/CR-UK Clinician Scientist Fellowship in Surgery, which supports a laboratory-based research programme at Barts Cancer Institute, Queen Mary University of London. Work in his laboratory focusses on how key genetic changes in prostate cancer cells allow them to become resistant to various treatments and spread to other parts of the body.


  1. The RNA-binding protein Sam68 regulates expression and transcription function of the androgen receptor splice variant AR-V7. Stockley J, Markert E, Zhou Y, Robson CN, Elliott DJ, Lindberg J, Leung HY*, Rajan P*. Sci Rep. 2015; 5:13426 PMID: 26310125 *Equal contributors 

  2. Feasibility study of a randomised controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration- resistant prostate cancer. Rajan P, Frew JA, Wilson JM, Azzabi AST, McMenemin RM, Stockley J, Soomro NA, Durkan G, Pedley ID, Leung HY. Urol Oncol. 2015; 33(8):337.e1-6 PMID: 26092557 

  3. Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer. Rajan P*, Stockley J*, Sudbery IM*, Fleming JT, Hedley A, Kalna G, Sims D, Ponting CP, Heger A, Robson CN, McMenemin RM, Pedley ID, Leung HY. BMC Cancer. 2014; 14:977 PMID: 25519703 *Equal contributors 

  4. The RNA-binding protein hnRNPA2 regulates β-catenin protein expression and is over-expressed in prostate cancer. Stockley J, Villasevil MEM, Nixon C, Ahmad I, Leung HY*, Rajan P*. RNA Biol. 2014; 11(6) PMID: 24823909 *Equal contributors 

  5. Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy. Rajan P*, Sudbery IM*, M. Eugenia M. Villasevil MEM, Mui E, Fleming J, Davis M, Ahmad I, Edwards J, Sansom OJ, Sims D, Ponting CP, Heger A, McMenemin RM, Pedley ID, Leung HY. Eur Urol. 2013; pii: S0302-2838(13)00832-4 PMID: 24054872 *Equal contributors 

  6. Identification of novel androgen-regulated pathways and mRNA isoforms through genome-wide exon- specific profiling of the LNCaP transcriptome. Rajan P*, Dalgliesh C*, Carling P, Buist T, Zhang C, Grellscheid SN, Armstrong K, Stockley J, Simillion C, Gaughan L, Kalna G, Zhang MQ, Robson CN, Leung HY, Elliott DJ. PLoS ONE 2011; 6(12): e29088 PMID: 22194994 *Equal contributors 

  7. Proteomic identification of heterogeneous nuclear ribonucleoprotein L as a novel component of SLM/Sam68 Nuclear Bodies. Rajan P*, Dalgliesh C*, Bourgeois CF, Heiner M, Emami K, Clark EL, Bindereif A, Stevenin J, Robson CN, Leung HY, Elliott DJ. BMC Cell Biol. 2009; 10:82 PMID: 19912651 *Equal contributors 

  8. The RNA-binding and adaptor protein Sam68 modulates signal-dependent splicing and transcriptional activity of the androgen receptor. Rajan P*, Gaughan L*, Dalgliesh C, El-Sherif A, Robson CN, Leung HY, Elliott DJ. J Pathol. 2008; 215(1):67-77 PMID: 18273831 *Equal contributors 

GMC/GDC number: 4766584 

 Web chat